C A R D I A C FA I L U R E R E V I E W
including 278 patients both demonstrated that exercise was safe for patients with acute decompensated HF (ADHF). 18, 19 The Rehabilitation ventricular assist device (Rehab-VAD) trial and the 2017 Cochrane review of exercise-based cardiac rehabilitation in heart transplant recipients demonstrated the safety of exercising with a LV assist device (LVAD) and orthotropic heart transplant (OHT), respectively. 20, 21 There has been investigation into the pathophysiology of exercise intolerance in patients with HF and the beneficial effects of exercise training. Mechanisms that may lead to decreased exercise capacity in this patient population include cardiac dysfunction, abnormalities in peripheral flow, endothelial dysfunction, skeletal muscle dysfunction, ventilatory deficits and abnormalities of autonomic nervous system function. 22 Exercise capacity is best quantified by peak oxygen consumption (peak VO 2 ) and many studies have demonstrated improvements in peak VO 2 with exercise training. 9, 11, [22] [23] [24] Additionally, exercise with moderate aerobic training has led to favourable effects on central haemodynamic function, sympathetic tone, peripheral vascular and skeletal muscle function, ventilatory efficiency with decreased dyspnoea and improved QoL. 22, 25, 26 Heart Failure with Reduced Ejection Fraction There is also evidence to support cost-effectiveness of exercisebased rehabilitation based on two trials included in the review that was attributed to a reduction in hospital bed days. 16 The 16, 17 In addition to demonstrating the safety of exercise with no major adverse effects reported in the 276 patients with well-compensated HFpEF in a meta-analysis that included six randomised controlled trials, it was suggested that exercise training improved cardiorespiratory fitness by an increase in peak VO 2 and QoL. 17 These improvements were noted to be unrelated to a significant change in the diastolic LV function.
The Exercise Training in Diastolic Heart Failure (Ex-DHF) pilot study was a randomised study involving 64 patients that compared supervised exercise or usual care and it demonstrated improvements in exercise capacity and health-related QoL. 30 There have been no studies evaluating the effect of exercise on hospitalisations or mortality in the HFpEF population, and HFpEF was excluded from CMS coverage for CR in the most recent decision memo in 2014. 15 The Ex-DHF trial, which is currently enrolling participants, is the first multicentre trial to evaluate the long-term effects of exercise on a composite outcome of all-cause mortality, hospitalisations, NYHA functional class, global self-rated heath, maximal exercise capacity, and diastolic function in HFpEF patients.
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Acute Decompensated Heart Failure
There is extremely limited data on the safety and clinical outcomes related to exercise therapy in people with ADHF, which is a leading cause of hospitalisation and is associated with significant morbidity, mortality, and healthcare costs, especially in older patients. These reduction, respectively, compared with those who did not participate in CR. 33 This was not the primary outcome of this study and there were likely additional confounding variables, although it suggests potential clinical benefits and identifies a need for further studies to evaluate the value of exercise in people with LVADs ( Figure 1A ).
Cardiac Transplantation
Although there have been significant improvements in OHTs over the past 40 years, long-term survival remains limited. Exercise capacity and health-related QoL in transplant recipients have been noted to be inferior compared with age-matched healthy people. 34 In the past, transplant patients were advised not to exercise due to concerns of chronotropic incompetence in the denervated heart, although further exercising to control and one study compared high-intensity to moderate-intensity training. 21 CR participation was associated with an improvement in peak VO 2 and exercise capacity, although there was no significant improvement in health-related QoL in a 12-week period. There was no data to report hospitalisations or mortality benefit in these studies. Additional studies have demonstrated improvement of peak heart rate, ventilatory capacity, autonomic function and QoL with exercise training. 36 In an evaluation of CR and readmission rates for 595
Medicare beneficiaries that received heart transplants in the US in 2013, 55% of patients were enrolled in CR. Participation in CR was associated with a 29% lower readmission risk at 1 year. 36 Younger patients (aged 35-49 years) were significantly less likely to enrol in CR, and those that enrolled were likely to attend fewer sessions that patients older then 65 years. There have been no published studies investigating the effects on mortality of OHT patients who have participated in exercise training or CR. Given the significant benefits of CR and the CMS coverage of CR in orthotopic heart transplant patients that was approved in 2006, there should be a significant effort to improve uptake of CR in this patient population ( Figure 1B ).
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CMS Coverage
In 2006, CMS published a decision that there was adequate evidence to approve coverage of CR for patients with an acute MI, coronary artery bypass graft, stable angina, heart valve repair or replacement, percutaneous transluminal coronary angioplasty or coronary stenting, and heart or heart and lung transplant ( Table 3) . 37 At that time, there was insufficient evidence to approve CR coverage for CHF patients.
After numerous studies were published demonstrating benefit of exercise training for patients with HFrEF, the largest of which being HF-ACTION, CMS expanded coverage for stable, chronic HF defined as patient with an LVEF ≤35% with NYHA II-IV symptoms despite optimal medical therapy for at least 6 weeks without recent or planned hospitalisation or procedure. 15 
Conclusion
CHF is an increasingly prevalent disease with significant morbidity and mortality despite optimal drug and device therapies. Despite numerous benefits in multiple HF groups, there is significant underuse of CR due to many barriers that need to be overcome.
Healthcare providers should strongly consider referring their patients with CHF to CR and encouraging participation in and adherence to exercise training programmes. 15 Stable chronic heart failure (LVEF ≤35%) and NYHA class II-IV symptoms despite optimal medical therapy for at least 6 weeks without recent (≤6 weeks) or planned (≤6 months) major cardiovascular hospitalisations or procedures. 
